Evidence map›Paper›PMID 39671022›Full record

ReviewMedical oncology (Northwood, London, England)2024

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.

Ali G Alkhathami, Harikumar Pallathadka, Sejal Shah, Subbulakshmi Ganesan, Abhishek Sharma, Seema Devi, Yasser Fakri Mustafa, Mohammed Qasim Alasheqi, Abed J Kadhim, Ahmed Hussein Zwamel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Chemoresistance: The hidden barrier in cancer treatment.Cancer pathogenesis and therapy · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ali G AlkhathamiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Harikumar PallathadkaManipur International University, Imphal, Manipur, India. Harikumar.impal.1980@gmail.com.
Sejal ShahDepartment of Bioinformatics, Faculty of Engineering and Technology, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, 360003, India.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to Be University), Bangalore, Karnataka, India.
Abhishek SharmaDepartment of Medicine, National Institute of Medical Sciences, NIMS University Rajasthan, Jaipur, India.
Seema DeviChandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali, Punjab, 140307, India.
Yasser Fakri MustafaDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq.
Mohammed Qasim AlasheqiCollege of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.
Abed J KadhimDepartment of Medical Engineering, Al-Nisour University College, Baghdad, Iraq.
Ahmed Hussein ZwamelMedical Laboratory Technique College, The Islamic University, Najaf, Iraq.

Funding

Deanship of Scientific Research, King Khalid University RGP.02/534/44
6 · The paper itself

Abstract

Paclitaxel (PTX) is widely used for treating several cancers, including breast, ovarian, lung, esophageal, gastric, pancreatic, and neck cancers. Despite its clinical utility, cancer recurrence frequently occurs in patients due to the development of resistance to PTX. Resistance mechanisms in cancer cells treated with PTX include alterations in β-tubulin, the target molecule involved in mitosis, activation of molecular pathways enabling drug efflux, and dysregulation of apoptosis-related proteins. Long non-coding RNAs (lncRNAs), which are RNA molecules longer than 200 nucleotides without protein-coding potential, serve diverse regulatory roles in cellular processes. Increasing evidence highlights the involvement of lncRNAs in cancer progression and their contribution to PTX resistance across various cancers. Consequently, lncRNAs have emerged as potential therapeutic targets for addressing drug resistance in cancer treatment. This review focuses on the current understanding of lncRNAs and their role in drug resistance mechanisms, aiming to encourage further investigation in this area. Key lncRNAs and their associated pathways linked to PTX resistance will be summarized.

Indexed as

Antineoplastic Agents, PhytogenicDrug Resistance, NeoplasmNeoplasmsPaclitaxelRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansAntineoplastic Agents, PhytogenicPaclitaxelRNA, Long NoncodingCancerLncRNAMechanismPaclitaxelResistance

Identifiers

PMID39671022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.